文献速递慢阻肺

比索洛尔预防慢阻肺患者不良心脏事件(PACE):多中心、双盲、随机、对照3期试验

Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2026-01-21

BACKGROUND: Although cardiovascular disease is common in patients with chronic obstructive pulmonary disease (COPD), the efficacy and safety of β blockers in reducing cardiac events and mortality is uncertain.…

要点

  • 对于中度至重度慢阻肺患者,比索洛尔并未改善整体心肺健康。
  • 比索洛尔未显著降低全因死亡率或严重心肺事件风险。
  • 比索洛尔组与安慰剂组的不良事件发生率无显著差异。

核心结论

  • 在中度至重度慢阻肺患者中,比索洛尔治疗对整体心肺健康、全因死亡率或严重心肺事件均无差异。

研究设计与样本

  • 多中心、双盲、随机、对照3期试验,在澳大利亚、印度、新西兰和斯里兰卡22个中心开展。
  • 主要终点为心脏和呼吸效应的复合终点,采用按国家分层的胜率法分析,意向性治疗分析。

主要发现

  • 全因死亡率、心肺住院、主要不良心脏事件、中重度慢阻肺急性加重均无显著差异。
  • FEV1、慢阻肺症状、生活质量及不良事件均无显著差异。
  • 最常见不良事件为慢阻肺急性加重,比索洛尔组83例(58%),安慰剂组87例(64%)。
  • 比索洛尔组死亡15例(10%),安慰剂组死亡11例(8%),无死亡归因于治疗。

临床怎么用

  • 对于中度至重度慢阻肺患者,不应期望比索洛尔能减少心脏事件或死亡。
  • 比索洛尔在慢阻肺患者中未显示额外的心肺获益,临床决策需权衡个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although cardiovascular disease is common in patients with chronic obstructive pulmonary disease (COPD), the efficacy and safety of β blockers in reducing cardiac events and mortality is uncertain. This study was designed to assess whether the cardioselective β blocker, bisoprolol, improves cardiorespiratory outcomes when added to usual COPD care. METHODS: This double-blind, randomised, controlled, phase 3 trial was done across 22 hospital and research institute sites selected by research experience and resources to conduct the study in Australia, India, New Zealand, and Sri Lanka. Participants aged 40-85 years with COPD, post-bronchodilator FEV1 30-70% predicted, and at least one COPD exacerbation in the previous 2 years were randomly assigned to receive bisoprolol (1·25-5 mg) or matched placebo, orally, once daily, for 2 years, with both groups continuing to receive usual COPD care. Randomisation was with a concealed, computer-generated sequence, stratified by site, smoking status, and previous diagnosis of cardiovascular disease requiring treatment. Participants, site personnel, and investigators remained masked to study treatment throughout the trial. The primary outcome was a composite of cardiac and respiratory effects, starting with the most important outcome (death), then cardiac or respiratory hospital admissions, exacerbations, quality-of-life measures, and FEV1. Analysis was by intention-to-treat (ITT) in all randomly assigned patients, using a country-stratified win ratio. Adverse events were analysed from the ITT population using all available data. Missing data were not used to determine wins, but regarded as a tie on that level of the hierarchy. The trial was prospectively registered on ClinicalTrials.gov (NCT03917914), Clinical Trial Registry - India (CTRI/2020/08/027322), and the Sri Lanka Clinical Trials Registry (SLCTR/2021/033). The study is complete. FINDINGS: Of 360 participants screened for eligibility between June 30, 2020, and March 20, 2023, 280 were randomly assigned to bisoprolol (n=143) or placebo (n=137), with 249 completing 2 years of follow-up. 233 patients (83%) were male and 47 (17%) were female; mean age was 68 years (SD 8). Mean post-bronchodilator FEV1 was 45% (SD 11) predicted at baseline. According to the hierarchy of outcomes, bisoprolol was associated with better cardiorespiratory health for 3041 (45%) of 6763 comparisons and placebo for 3240 (48%), with 482 (7%) showing no difference, giving a win ratio of 0·95 (95% CI 0·72 to 1·25, p=0·72) and a net benefit of -2% (95% CI -15 to 10) with bisoprolol. No significant differences were seen between bisoprolol and placebo in all-cause mortality, cardiorespiratory hospitalisations, major adverse cardiac events, or moderate or severe COPD exacerbations. Additionally, no significant differences were seen in FEV1, COPD symptoms, or quality of life, or adverse events. The most common adverse events were COPD exacerbations, occuring in 83 (58%) participants in the bisoprolol group and 87 (64%) in the placebo group. 15 (10%) participants in the bisoprolol group and 11 (8%) in the placebo group died. None of these deaths were attributed to the treatment. INTERPRETATION: In patients with moderately severe COPD, treatment with bisoprolol made no difference to overall cardiorespiratory health, all-cause mortality, or serious cardiorespiratory events. FUNDING: National Health and Medical Research Council of Australia and the Health Research Council of New Zealand.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Jenkins, Martin, Chang, et al. Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Respir Med. 2026. PMID: 41579873. doi:10.1016/S2213-2600(25)00390-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。